1. Abman S.H., Pediatr. Pulmonol. Suppl., 1999, 18, 201.
2. Alwan S. et al., NEJM, 2007, 356, 2684.
3. Bandelow B. et al., J. Clin. Psychiatry, 2004, 65 (3), 405.
4. Boer R.A. et al., BMC Emergency Medicine, 2005, 5, 5.
5. Carson H.J. et al., Am. J. Forensic Med. Pathol., 2000, 21, 273.
6. Casper R.C. et al., J. Pediatr., 2003, 142, 402.
7. Chambers C.D. et al., NEJM, 2006, 354, 579.
8. Dalton S.O. et al., Arch. Intern. Med., 2003, 163, 59.
9. De Abajo F.J. et al., BMJ, 1999, 319, 1106.
10. Doogan D.P., Caillard V., Br. J. Psychiatry, 1992, 160, 217.
11. Drug Ther. Bull., 1991, 4 (13), 51.
12. Expertise Collective Inserm, Les édition Inserm: Paris; 2003.
13. Fisekonc' S., Loga-Zec S., Bosn. J. Basic Med. Sci., 2005, 5 (2), 78.
14. Glassman A.H. et al., JAMA, 2002, 288, 701.
15. Gulseren L. et al., Arch. Med. Res., 2005, 36 (2), 159.
16. Hoechns J.D. et al., Ann. Pharmacother., 2001, 35, 862.
17. Kmijima K. et al., Int. Clin. Psychopharmacol., 2005, 20 5), 265.
18. Kirby D. et al., Internet J. Ger. Psychiatry, 2002, 17, 231.
19. Jureidini J.N. et al., BMJ, 2004, 328, 879.
20. Laine K. et al., Arch. Gen. Psychiatry, 2003, 60, 720.
21. Layton D. et al., Eur. J. Clin. Pharmacol., 2001, 57, 167.
22. Louik C. et al., NEJM, 2007, 356, 2675.
23. Malm H. et al., Obstet. Gynecol., 2005, 106, 1289.
24. Markowitz J.S., DeVane C.L., J. Clin. Psychopharmacol., 2000, 20, 109.
25. Mason P.J. et al., Medicine, 2000, 79, 201.
26. Mills J.L., NEJM, 2006, 354, 636.
27. Morag I. et al., J. Toxicol. Clin. 2004, 42, 97.
28. Movig K.L. et al., Arch. Intern. Med., 2003, 163, 2354.
29. Murdock D., McTavish D., Drugs, 1992, 44 (4), 604.
30. Nace D.A., Towers A., J. Am. Ger. Soc., 1999, 47, S32.
31. NICE – National Institute for Health and Clinical Excellence, 2007, disponibile online www.nice.org.uk/nicemedia/pdf/CG23fullguideline.pdf
32. Nielsen J.A. et al., Am. J. Clin. Nutr., 1992, 55, 185S.
33. Nulman I. et al., Am. J. Psychiatry, 2002, 159, 1889.
34. Oberlander T.F. et al., Pediatr. Res., 2002, 51, 443.
35. Orlova Y. et al., JAMA Neurol., 2018, doi: 10.1001/jamaneurol.2017.5144.
36. Patron C. Ferrier I.N., BMJ, 2005, 334, 529.
37. Rey J. et al., Rheumatology, 2003, 42, 601.
38. Sansone R.A., Sansone L.A., Int. J. Psychiatry Med., 2003, 33 (1), 103.
39. Serebruany V.L., Am. J. Med., 2006, 119, 113.
40. Stone Z.N. et al., Am. J. Psychiatry, 1997, 154, 1255.
41. Trenque T. et al., Pharmacoepidemiol. Drug Safety, 2002, 11, 281.
42. van Walraven C. et al., BMJ, 2001, 323, 655.
43. Yonkers K.A. et al., JAMA, 1997, 278, 983.
44. Wagner K.D. et al., JAMA, 2003, 290, 1033.
45. Walkup J.T. et al., NEJM, 2008, 359, 2753.
46. Warrington S.J., Int. Clin. Psychopharmacol., 1991, 6 (Suppl. 2), 11.
47. Weissman A.M. et al., Am. J. Psychiatry, 2004, 161, 1066.
48. Zeskind P.S., Stephens L.E., Pediatrics, 2004, 113, 368.
49. Zeskind P.S. et al., Pediatr. Res., 2005, 57, 1624.